Alpha Teknova, Inc. (TKNO)

Alpha Teknova's stock price has experienced significant fluctuations in the past six months. The stock declined by 51% over the past six months, but has risen over 329.44% since its lowest point on July 8, 2024. The company reported its second-quarter 2025 earnings on August 7, 2025, with an EPS loss of $0.07, beating the forecast, and revenue up 7% year-over-year to $10.3 million, exceeding expectations. Following this announcement, the stock declined by 2.5% the next day. Earlier, on May 8, 2025, Alpha Teknova reported first-quarter EPS of $-0.09, which was better than analyst estimates. In March 2025, the company announced a collaboration with Pluristyx to commercialize the PluriFreeze Cryopreservation System for cell therapies. A private placement in July 2024 involved the issuance and sale of over 12 million shares of common stock, generating approximately $15.4 million in gross proceeds for general corporate purposes.

Demand for Alpha Teknova's products varies across its segments. The "Lab Essentials" segment, which constitutes 75% of the company's revenue, provides stability. Revenue from the "Clinical Solutions" segment can experience quarter-to-quarter fluctuations due to the timing of customer orders and project cycles. The broader biotech sector faces macroeconomic pressures, including high interest rates and inflation, which can influence overall demand.

Alpha Teknova, Inc. is a life sciences company focused on producing critical reagents for the development and commercialization of therapies, vaccines, and diagnostics. It operates in the Health Technology sector, specifically Biotechnology: In Vitro & In Vivo Diagnostic Substances, and is also categorized under Pharmaceuticals: Major. The company's products include pre-poured media plates, liquid cell culture media, and molecular biology reagents, serving pharmaceutical and biotechnology companies, contract manufacturers, diagnostic franchises, and research institutions.

Alpha Teknova, Inc. is headquartered in Hollister, California, United States, and has an international presence, providing its in vitro diagnostics (IVD) products across the European Union, Asia Pacific, North America, South America, and Africa.

Alpha Teknova has an established brand reputation built over more than 25 years, known for its ability to offer customer-specified RUO and GMP formulations with short turnaround times, along with technical expertise. The company has been active in presenting data on novel products to accelerate the development of AAV therapies and announced a collaboration with Pluristyx to streamline the manufacture of next-generation cell therapies, which generally contribute positively to its scientific standing and industry perception.

Alpha Teknova, Inc. has a diverse ownership structure, with approximately 14.34% held by institutional shareholders, 64.16% by Alpha Teknova insiders, and 21.50% by retail investors. Major institutional shareholders include UBS Group AG, Balyasny Asset Management Llc, BlackRock, Inc., Vanguard Group Inc, Roubaix Capital, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, CenterBook Partners LP, Geode Capital Management, Llc, Goldman Sachs Group Inc, and IWM - iShares Russell 2000 ETF. The largest individual shareholder is Telegraph Hill Partners IV LP, owning 25.62 million shares, representing 47.94% of the company. Other significant insider owners include Ted Davis and Irene Davis.